Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Adagrasib

            Therapeutic Area: Oncology Product Name: MRTX849

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Mirati Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 25, 2021

            Details:

            QIAGEN is developing a tissue-based companion diagnostic to identify patients with cancers that have a KRASG12C mutation who may benefit from treatment with adagrasib, Mirati’s investigational, highly selective and potent oral small molecule inhibitor of KRASG12C.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Copanlisib,Rituximab

            Therapeutic Area: Oncology Product Name: Aliqopa

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 10, 2021

            Details:

            In the Phase III trial CHRONOS-3 of 458 patients with indolent non-Hodgkin’s Lymphoma, the investigational combination of Aliqopa and rituximab was statistically significant in delaying disease progression or death compared to rituximab and placebo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VGX-3100

            Therapeutic Area: Oncology Product Name: VGX-3100

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Inovio Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 24, 2021

            Details:

            The initial project in this expanded collaboration focuses on the co-development of a diagnostic test that identifies women who are most likely to benefit from clinical use of VGX-3100, INOVIO's immunotherapy to treat advanced cervical dysplasia associated with HPV.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Copanlisib,Rituximab

            Therapeutic Area: Oncology Product Name: Aliqopa

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 14, 2020

            Details:

            Phase III study CHRONOS-3 in patients with relapsed indolent Non-Hodgkin's Lymphoma (iNHL) who have received one or more prior lines of rituximab-containing therapy meets primary endpoint of progression-free survival .

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Darolutamide

            Therapeutic Area: Oncology Product Name: Nubeqa

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 03, 2020

            Details:

            The study was double-blind until metastases or unacceptable toxicity occurred. After unblinding, the patients could choose to continue their darolutamide plus ADT treatment or receive darolutamide instead of placebo.